Sight Sciences Management

Management Kriterienprüfungen 3/4

Sight Sciences' CEO is Paul Badawi, appointed in Jan 2011, has a tenure of 13.83 years. total yearly compensation is $3.90M, comprised of 15.6% salary and 84.4% bonuses, including company stock and options. directly owns 11.38% of the company’s shares, worth $29.83M. The average tenure of the management team and the board of directors is 4.6 years and 4.7 years respectively.

Wichtige Informationen

Paul Badawi

Geschäftsführender

US$3.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	15.6%
Amtszeit als Geschäftsführer	13.8yrs
Eigentum des Geschäftsführers	11.4%
Durchschnittliche Amtszeit des Managements	4.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.7yrs

Jüngste Management Updates

Recent updates

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Aug 15

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Jul 12

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 19

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Paul Badawi im Vergleich zu den Einnahmen von Sight Sciences verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$52m
Mar 31 2024	n/a	n/a	-US$55m
Dec 31 2023	US$4m	US$610k	-US$56m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$80m
Dec 31 2022	US$6m	US$580k	-US$86m
Sep 30 2022	n/a	n/a	-US$85m
Jun 30 2022	n/a	n/a	-US$80m
Mar 31 2022	n/a	n/a	-US$74m
Dec 31 2021	US$9m	US$424k	-US$63m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$497k	US$360k	-US$35m

Vergütung im Vergleich zum Markt: Paul's total compensation ($USD3.90M) is above average for companies of similar size in the US market ($USD1.48M).

Entschädigung vs. Einkommen: Paul's compensation has been consistent with company performance over the past year.

Geschäftsführer

Paul Badawi (49 yo)

13.8yrs

Amtszeit

US$3,902,022

Vergütung

Mr. Paul Badawi is a Co-Founder of Sight Sciences, Inc. since 2011 and serves as its President and Chief Executive Officer since 2011. Mr. Badawi specializes in medical technology investments for 3i. His p...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Paul Badawi	Co-Founder	13.8yrs	US$3.90m	11.38% $ 29.8m
David Badawi	Founder	13.8yrs	keine Daten	3.49% $ 9.2m
Alison Bauerlein	CFO & Treasurer	1.6yrs	US$1.85m	0.12% $ 307.5k
Matthew Link	Chief Commercial Officer	1.2yrs	US$2.36m	0.20% $ 536.0k
Sam Park	Chief Operating Officer	4.7yrs	US$1.86m	0.17% $ 442.0k
Jeremy Hayden	Chief Legal Officer	4.6yrs	keine Daten	0.32% $ 826.8k
Steve Tamayo	VP and Chief Ethics & Compliance Officer	1.5yrs	keine Daten	keine Daten
Reay Brown	Chief Medical Officer	6.1yrs	keine Daten	keine Daten
Stephen Thau	Secretary	no data	keine Daten	keine Daten
Jim Rodberg	VP of Finance & Corporate Controller	no data	keine Daten	0.0014% $ 3.6k

4.6yrs

Durchschnittliche Betriebszugehörigkeit

51.5yo

Durchschnittliches Alter

Erfahrenes Management: SGHT's management team is considered experienced (4.6 years average tenure).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Paul Badawi	Co-Founder	13.8yrs	US$3.90m	11.38% $ 29.8m
David Badawi	Founder	13.8yrs	keine Daten	3.49% $ 9.2m
Erica Rogers	Independent Director	5yrs	US$182.30k	0.22% $ 575.8k
Donald Zurbay	Independent Director	4.4yrs	US$187.50k	0.20% $ 521.5k
Brenda Becker	Independent Director	2.7yrs	US$167.33k	0.0073% $ 19.2k
Staffan Encrantz	Independent Chairman	7.1yrs	US$207.91k	4.37% $ 11.4m
Tamara Fountain	Independent Director	2.3yrs	US$401.06k	0.042% $ 109.8k
Catherine Mazzacco	Independent Director	1.4yrs	US$256.34k	0.036% $ 94.9k

4.7yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: SGHT's board of directors are considered experienced (4.7 years average tenure).

Sight Sciences Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Chief Commercial Officer recently sold US$245k worth of stock

Chief Commercial Officer notifies of intention to sell stock

Co-Founder recently sold US$76k worth of stock

CFO & Treasurer notifies of intention to sell stock

Co-Founder recently sold US$81k worth of stock

CFO & Treasurer recently sold US$71k worth of stock

Recent updates

Chief Commercial Officer recently sold US$245k worth of stock

Chief Commercial Officer notifies of intention to sell stock

Sight Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Co-Founder recently sold US$76k worth of stock

CFO & Treasurer notifies of intention to sell stock

Price target increased by 14% to US$7.38

Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge

Second quarter 2024 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Narrows Earnings Guidance for the Full Year 2024

Sight Sciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?

Co-Founder recently sold US$81k worth of stock

Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma

CFO & Treasurer recently sold US$71k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024

Sight Sciences, Inc., Annual General Meeting, Jun 06, 2024

Sight Sciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study

Co-Founder recently sold US$64k worth of stock

Sight Sciences, Inc. Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT At the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Provides Earnings Guidance for the Year 2024

New minor risk - Insider selling

Sight Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting

Sight Sciences, Inc. announced that it expects to receive $65 million in funding

Co-Founder recently sold US$82k worth of stock

Co-Founder notifies of intention to sell stock

Sight Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Sight Sciences, Inc. (NASDAQ:SGHT) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Sight Sciences, Inc. Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Sight Sciences Announces the Acceptance for Publication of Gemini 2, A Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant Iop and Medication Reductions Enabled with the Omni® Surgical System Technology

Independent Chairman recently bought US$278k worth of stock

Some Analysts Just Cut Their Sight Sciences, Inc. (NASDAQ:SGHT) Estimates

Price target decreased by 49% to US$3.13

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023

New minor risk - Market cap size

Sight Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sight Sciences, Inc. Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Chief Operating Officer exercised options to buy US$130k worth of stock.

Sight Sciences, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 8.1% to US$10.48

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sight Sciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Sight Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 12% to US$12.80

Sight Sciences Announces Appointment of Catherine Mazzacco as New Director

Sight Sciences Two Year Multicenter Study Results Shows Sustained Reductions in Both Intraocular Pressure and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with A Procedure Enabled with the Omni Surgical System Technology

Sight Sciences, Inc. Announces 12-Month Results from the First Minimally Invasive Glaucoma Surgery

First quarter 2023 earnings: EPS exceeds analyst expectations

Sight Sciences Reaffirms Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Sight Sciences, Inc. Announces Executive Changes

Price target increased to US$14.60

Sight Sciences, Inc. Reports Improvements in Signs and Symptoms of Dry Eye Disease from A Single Tearcare

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Sight Sciences, Inc. Provides Revenue Guidance for Full Year 2022

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients

Sight Sciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Sight Sciences, Inc. Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare(R) System Compared to Lipiflow in Patients with Advanced Dry Eye Disease (DED)

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare(R) System vs Restasis

Sight Sciences Introduces the Sion(Tm) Surgical Instrument -- the First Bladeless Device Used in Goniotomy

Sight Sciences Grows Portfolio Amid Reimbursement Pressure